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Abstract
Urinary stone disease is a highly prevalent urological condition; however, the
pathophysiology remains poorly understood. Growing evidence suggests a relationship
between urinary tract infections, antibiotic exposure and the development of urolithiasis. In
this project, we utilized a dietary Drosophila melanogaster model and a calcium oxalate
crystal adhesion assay to further investigate the impact of a urinary pathogen and antibiotics
on calcium stone formation. We demonstrated that both a non-urease producing strain of
Escherichia coli and the antibiotics, ciprofloxacin and trimethoprim-sulfamethoxazole,
increased calcium stone formation. In addition, our preliminary work suggests that
biomineralization agents such as osteopontin and zinc appear to be implicated in this process.
Further research is required to better delineate the mechanisms involved and to translate
these findings into potential therapeutic and prevention strategies for human stone disease
including antibiotic stewardship, anti-oxidants, probiotics, and microbiome modification.
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Chapter 1

1

Introduction

Urinary stone disease is a highly prevalent condition which affects approximately 10% of
the adult population, and has been shown to have increased in incidence significantly
over the past twenty years1. While mortality resulting from urinary stone disease is rare
with modern medical treatment, the condition still results in significant morbidity
including acute renal colic, chronic kidney disease and urosepsis. In addition, urolithiasis
has a high recurrence rate of approximately 50% at ten years without preventative
treatment2. As a result, urinary stone disease places a tremendous burden on the health
care system with an estimated 185,000 hospitalizations, 2 million outpatient visits, and
2.1 billion dollars expended in the United States annually3,4. Current dietary and
pharmacological treatment strategies have led to only a modest improvement in stone
recurrence rates. Consequently, an improved understanding of the pathophysiology of
stone development is paramount to developing more efficacious prevention strategies5,6,7.
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1.1

Epidemiology of Urolithiasis

Urinary stone disease is a common condition worldwide, with incidence rates ranging
from 7-13% in North America, 5-9% in Europe, and 1-5% in Asia1. In addition, multiple
reports have demonstrated an increasing prevalence of stone disease across the globe over
the past several decades. The prevalence rate was shown to have risen a dramatic 37% in
American adults from 1976 to 19948. Comparable increases have also been observed in
Japan and Iceland, where the annual incidence has been observed to triple. In Japan, the
annual incidence of first-episode urinary stone disease rose from 54.2 to 134.0 per
100,000 from 1965 to 20059. Similarly, the incidence of stone disease in Iceland
increased from 7 to 24 per 100,000 over a twenty-four-year period10. Multiple theories
have been proposed to explain this trend including the increased use of abdominal
imaging leading to higher rates of diagnosis for asymptomatic stones, and global
warming resulting in expansion of areas at high risk for dehydration and subsequent stone
formation1. In addition, the dramatic rise of conditions associated with stone formation
including obesity, diabetes mellitus, and metabolic syndrome are likely also contributing
to the rising incidence of urolithiasis1. Along with this, changing dietary patterns which
include decreased water and calcium consumption, and increased intake of dietary
sodium, animal protein and sweetened soft drinks has also been linked with stone
disease1.
However, the rising incidence of stone disease has been most pronounced in populations
which have typically been thought to be at lower risk for urolithiasis, such as women and
children. In the latter, the incidence of stone disease has increased a startling 4%
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annually over the past twenty-five years11. Similarly, the incidence of stone disease has
been observed to rise an average of 1.9% per year from 1970 to 2000 in American
women12. In addition, multiple reports have demonstrated a narrowing of the gender gap
in the prevalence of stone disease between males and females12,13,14. A recent report
examining data from the National Health and Nutrition Examination Survey (NHANES)
from 2007 to 2012 failed to show any differences in stone prevalence between males and
females; suggesting that the long held gender gap in stone disease may be closing15.
While the substantial increase in urolithiasis has been partially attributed to the
significant rise of obesity and diabetes, the potential causes behind the changing
demographics of stone disease has yet to be fully elucidated1.

1.2

Clinical Presentation of Urolithiasis

Pain is the most common symptom associated with urolithiasis and results from the
obstruction of urine by the stone. The pain is typically colicky in nature and may be
accompanied by nausea and vomiting. Distention of the renal capsule from
hydronephrosis results in nausea and vomiting due to the shared splanchnic innervation
of the gastrointestinal tract and the renal capsule16. Patients will typically experience
unilateral flank pain which radiates to the ipsilateral groin with calculi within the upper
urinary tract. As the stone migrates more distally into the lower ureter, the pain may
radiate to the testicle or labium and be associated with irritative voiding symptoms such
as urinary urgency and frequency16.
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Pain is frequently accompanied with hematuria and up to 85% of patients will experience
either gross or microscopic hematuria during their acute stone episode17. In addition, a
number of patients with stone disease may also present with painless hematuria resulting
in diagnosis.
Patients may occasionally present with renal dysfunction secondary to urinary obstruction
in the setting of a solitary kidney, bilateral obstructing calculi, pre-existing renal
insufficiency, or prolonged obstruction. Furthermore, patients can also present with fever
or urosepsis resulting from a urinary infection combined with urinary obstruction.
Finally, an increasing number of patients are now being diagnosed with asymptomatic
urolithiasis detected incidentally on abdominal imaging for unrelated indications given
the widespread availability of multiple imaging modalities18.

1.3

Pathogenesis of Urolithiasis

Despite years of extensive investigation, the pathogenesis and physiochemistry
mechanisms of stone formation remain incompletely understood19. The formation of a
urinary calculi is a complex cascade of events that begins with supersaturation of the
urine with stone-forming solutes; following this, crystals become retained within the
kidney at anchoring sites allowing for further crystal growth and aggregation20.
Supersaturation of the urine with lithogenic solutes is influenced by several etiological
factors including the increased production or excretion of the specific solute and urinary
pH which modifies the solubility of the solute within the urine21. Once there is

5

supersaturation of a solute, homogenous nucleation occurs forming a crystal nuclei21.
The crystal nuclei are small and can often be destabilized by stone inhibitors in the urine
such as citrate, magnesium, and nephrocalcin; which result in the dissolution of the
nuclei22. However, stone promoters within the urine can act to stabilize the nuclei
allowing for further crystal growth and aggregation22.
Fixed particle growth theory postulates that stone crystals bind to an anchoring site
within the kidney resulting in prolonged exposure of the crystal to supersaturated urine
thereby facilitating further crystal growth and aggregation23. While the mechanism
behind crystal fixation is not fully understood, it has been proposed that high levels of
urinary oxalate lead to renal tubular epithelial cell damage and result in increased
adherence of calcium oxalate (CaOx) crystals23. It is thought that oxalate-induced cell
injury is mediated through oxidative stress and reactive oxygen species (ROS). In
addition, oxidative stress has been suggested as a potential mechanism to explain the
association between stone disease and other conditions associated with high levels of
oxidative stress such as diabetes and metabolic syndrome24.

1.4

Classification of Urolithiasis

Urolithiasis is most commonly classified according to stone composition and includes
calcium-based, uric acid, struvite, and cystine stones (table 1)25. The majority of calculi
are heterogeneous in composition reflecting the complex physiochemistry involved in
stone formation. Calcium-based stones are the most prevalent stone type (80%) and are
typically comprised of CaOx (70%) in either the monohydrate (COM) or dihydrate
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(COD) form25. Calcium phosphate encompasses a much smaller percentage of calciumbased stones (10%). In addition, calcium stones may also contain small amounts of
hydroxyapatite and uric acid. Uric acid stones are the second most common stone
composition (7%) and may contain small amounts of hydroxyapatite and struvite.
Struvite calculi (7%), which are magnesium ammonium phosphate stones, are typically
associated with urinary infection with urease-splitting organisms. Cystine stones, which
are a rare stone type (3%), are formed as a result of the autosomal recessive genetic
disorder cystinuria. Finally, there are a number of other rare stone types such as xanthine
and multiple drug related stones (triamterene, indinavir) which can occur25.

7

Table 1: Classification of urolithiasis by stone composition and occurrence25.
Stone Composition

Occurrence (%)25

Stone Constituents

Calcium oxalate

60

Monohydrate (Whewellite)
Dihydrate (Weddellite)

Calcium phosphate

20

Brushite
Hydroxyapatite

Uric acid

7

Uric acid
Monosodium urate

Struvite

7

Ammonium-magnesium phosphate

Cystine

3

Cystine

<1

Xanthine
Triamterene
Indinavir

Miscellaneous

8

1.4.1

Calcium Oxalate

Despite being the most commonly encountered stone type, the etiology of CaOx
urolithiasis is poorly understood and likely results from the complex interplay of many
genetic and environmental factors. Many conditions and metabolic abnormalities have
been identified which predispose to CaOx stone formation including hypercalciuria,
hyperoxaluria, hyperuricosuria, and hypocitraturia. However, a significant proportion of
CaOx stone formers are idiopathic highlighting our incomplete understanding of the
pathophysiology of calcium stone disease.

1.4.1.1

Hypercalciuria

Hypercalciuria is a common metabolic disturbance in calcium stone formers and is
identified in 35-65% of patients26. Hypercalciuria is defined as excretion of greater than
4 mg/kg/day of calcium within the urine and results in an increased risk of stone
formation through increased supersaturation of the urine and reduced activity of urinary
stone inhibitors27. The causes of hypercalciuria can be broadly categorized as absorptive,
resorptive, renal leak and idiopathic; however, hypercalciuria likely results from multiple
interrelated physiological disturbances. Absorptive hypercalciuria occurs when there is
increased intestinal absorption of calcium which is matched by a proportional increase in
renal calcium excretion by the kidney. The mechanism behind absorptive hypercalciuria
has not been fully elucidated; however, it has been linked to a number of genetic
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abnormalities which alter vitamin D activity such as mutations in the CYP24A1 or
vitamin D receptor (VDR) gene28,29.
Renal leak hypercalciuria occurs when the renal tubule fails to absorb an adequate
amount of calcium resulting in elevated urinary calcium levels and secondary
hyperparathyroidism30. Similarly, the precise cause of renal leak hypercalciuria remains
unknown. It has been associated with several genetic mutations which affect a number of
transport channels within the tubule31,32.
Resorptive hypercalciuria is an infrequently encountered cause of hypercalciuria which
most commonly results from primary hyperparathyroidism. Only approximately 5% of
cases of nephrolithiasis are associated with primary hyperparathyroidism33. In primary
hyperparathyroidism excessive parathyroid hormone (PTH) secretion from a parathyroid
adenoma results in elevated serum calcium and thus increased urinary excretion of
calcium. The elevated serum calcium results from excessive bone resorption and
increased renal synthesis of 1,25(OH)2D3 which in turn increases intestinal absorption of
calcium. Interestingly, only 25-55% of patients with primary hyperparathyroidism will
be affected with urolithiasis, suggesting that the etiology of stones requires more than
isolated hypercalciuria and remains incompletely understood34. There are additional rarer
causes of resorptive hypercalciuria including malignancy, granulomatous diseases,
thyrotoxicosis and vitamin D toxicity35.
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1.4.1.2

Hyperoxaluria

In addition to hypercalciuria, a proportion of CaOx stone formers (2-15%) will have
hyperoxaluria, which is defined as a urinary oxalate excretion of greater than 40mg/day26.
Elevated urinary oxalate levels contribute to the supersaturation of CaOx and reduced
activity of stone inhibitors; however, oxalate may further propagate crystal adherence and
growth by causing renal tubular damage through oxidative stress and ROS36. Antioxidant
therapy has been demonstrated to prevent CaOx crystal deposition in renal urothelium
both in vitro and in rat kidneys36,37. The causes of hyperoxaluria can be categorized as
either primary, enteric, or dietary forms.
Primary hyperoxaluria is a rare autosomal recessive genetic condition in glyoxylate
metabolism which results in the excessive production and subsequent urinary excretion of
oxalate. In this condition, the normal conversion of glyoxylate to glycine is prevented
and thus glyoxylate is preferentially converted to oxalate. The markedly elevated levels
of urinary oxalate result in the supersaturation of CaOx within the urine and subsequent
stone formation. In addition, CaOx crystals are internalized into tubular cells and then
extruded into the renal interstitium resulting in nephrocalcinosis38.
Dietary hyperoxaluria occurs from the over indulgence of foods rich in oxalate such as
spinach, rhubarb, nuts, chocolate and tea. Exogenous oxalate contributes to 24 to 42% of
excreted urinary oxalate39. In addition, diets low in calcium intake can result in increased
intestinal oxalate absorption due to the reduced intestinal binding of oxalate. Finally,
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ascorbic acid is converted to oxalate and can also increase urinary oxalate levels, and has
been associated with increased stone formation40,41.
The most common cause of acquired hyperoxaluria is the enteric form. This occurs when
malabsorptive states result in fatty acid saponification with cations such as calcium and
magnesium, thereby reducing the intestinal binding of calcium and oxalate and increasing
intestinal oxalate absorption42. In addition, the poorly absorbed fatty acids have been
shown to increase colonic permeability to oxalate resulting in a further increase in oxalate
absorption43,44. Conditions associated with enteric hyperoxaluria include chronic
diarrheal states, prior small bowel resection, intrinsic disease, and jejunoileal bypass45.
The prevalence of enteric hyperoxaluria is especially important in patients undergoing
malabsorptive bariatric surgery as these patients commonly have a number of other
baseline metabolic derangements that put them at higher risk for stone formation.
Unfortunately, this is becoming an increasingly encountered clinical scenario with the
rise of the obesity epidemic.
The intestinal absorption of oxalate has also been associated with the bacterium
Oxalobacter formigenes which is a gram-negative, obligatory anaerobic bacterium which
colonizes the intestinal tract of humans46. Oxalobacter formigenes utilizes oxalate as its
primary carbon source through the oxalyl-CoA decarboxylase enzyme, and as a result it
has been theorized that colonization with O. formigenes can impact the intestinal
absorption of oxalate and thus urinary oxalate excretion47. Previous studies have
demonstrated colonization with O. formigenes resulted in reduced urinary oxalate
excretion, reduced plasma oxalate, and a lower risk of developing CaOx stone disease4851

. Prolonged antibiotic use appears to negatively impact O. formigenes colonization and
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may represent one of the mechanisms by which antibiotics affect stone formation.
Patients with cystic fibrosis and Helicobacter pylori infection who are often treated with
prolonged courses of antibiotics have been demonstrated to have an absence of O.
formigenes colonization and as a result elevated urinary oxalate levels52,53.

1.4.1.3

Hyperuricosuria

Hyperuricosuria defined as a urinary uric acid level exceeding 600mg per day has also
been associated with an increased risk of CaOx stone formation and is found in up to
10% of calcium stone formers54. It is thought that elevated levels of urinary uric acid
increase CaOx stone formation through the process of heterogeneous nucleation by
providing a nidus for further crystal aggregation and growth55. Uric acid has also been
shown to reduce the effectiveness of multiple urinary stone inhibitors56. The most
common cause of hyperuricosuria is elevated dietary purine intake. A number of other
conditions associated with altered purine metabolism such as Lesch-Nyhan Syndrome
and gout; as well as conditions associated with rapid tissue turnover including
myeloproliferative disorders, and multiple myeloma can also result in hyperuricosuria
and uric acid stone formation57.
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1.4.1.4

Hypocitraturia

Hypocitraturia occurs in approximately 10% of calcium stone formers and is defined as a
urinary citrate level less than 320 mg/day58. Citrate acts as an important inhibitor of
stone formation through several different mechanisms. It has been shown to reduce
urinary saturation of calcium, prevent spontaneous nucleation of CaOx, inhibit
aggregation and growth of CaOx crystals, and enhance the effect of other stone
inhibitors59-63. Urinary citrate excretion is primarily determined by acid-base balance and
metabolic acidosis will reduce urinary citrate levels through increased tubular
reabsorption and decreased citrate synthesis in the peritubular cells64. Hypocitraturia can
result from a number of disease states including chronic diarrheal states, excessive animal
protein intake, medications such as thiazide diuretics and angiotensin-converting
enzymes, and distal renal tubular acidosis (RTA).
In addition, there are a number of other abnormalities which have been associated with an
increased risk of CaOx stone disease such as low urine pH, hypomagnesuria and low
urine volume. A significant proportion of CaOx stone formers will have multiple
different metabolic abnormalities detected, and approximately 3% of patients will
demonstrate no abnormality on their metabolic evaluation65. The overall pathogenesis of
CaOx stone formation is not completely understood and is likely a complex process
involving the interplay of multiple different mechanisms.

14

1.4.2

Uric Acid

Uric acid is formed as a byproduct of purine metabolism and can accumulate
significantly within human blood and urine resulting in uric acid stones66. The formation
of uric acid stones is determined by urinary pH, hyperuricosuria, and low urine volumes.
Uric acid can be present as either free uric acid or urate salt, depending on the pH. Urate
salt is approximately twenty times more soluble than free uric acid and consequently, the
risk of uric acid stone formation is highly dependent on urine pH67. For instance, at a
urinary pH of 5 the supersaturation of uric acid is easily reached with the excretion of
normal amounts of uric acid; however, increasing the urinary pH to 6.5 allows for
significantly higher concentrations of uric acid to remain soluble within the urine67.
Conditions associated with low urine pH and low urine volumes such as intestinal
malabsorption and chronic diarrheal states are at increased risk for uric acid urolithiasis
due to a loss of bicarbonate and concentrated acidic urine68. In addition, type two
diabetes and metabolic syndrome has also been demonstrated to be a risk factor for uric
acid stone formation by reducing ammoniagenesis and lowering urinary pH69.
Hyperuricosuria can also result in the formation of uric acid urolithiasis through
extremely elevated levels of urinary uric acid which crystallize regardless of urinary pH.
This can be found in patients with gout, myeloproliferative disorders, and tumor lysis
syndrome.
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1.4.3

Struvite

Struvite stones which are classically referred to as infection stones are composed
primarily of magnesium ammonium phosphate and occur following urinary infection
with a urease splitting organism. The process of urea-lysis provides an alkaline
environment as well as sufficient concentrations of carbonate and ammonia which allow
the production of struvite stones70. Urea, which is a normal constituent of urine, is
hydrolyzed to ammonia by bacterial urease70. This results in alkaline urine which favors
the formation of ammonium and further increases the urinary pH70. This promotes the
formation of carbonate and phosphate which along with physiologic concentrations of
magnesium provide the constituents for struvite formation (figure 1)70.
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Figure 1: Chemical reactions leading to the formation of infection based urinary
calculi.
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The most commonly encountered urease-splitting pathogens include Proteus, Klebsiella,
Pseudomonas and Staphylococcus species; however, a number of gram-positive and
gram-negative bacteria as well as yeast species have demonstrated the ability to
synthesize urease (table 2)71. Escherichia coli which is a common organism in urinary
tract infections (UTIs) only rarely produces urease72. In addition to the ability to
synthesize urease, bacteria may further propagate stone formation by causing urothelial
damage allowing for increased bacterial colonization and crystal adherence73,74.
Furthermore, certain bacteria have also been observed to reduce the activity of certain
urinary stone inhibitors such as urokinase75.
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Table 2: Urease producing organisms.
Gram-negative
Proteus rettgeri
Proteus vulgaris
Proteus mirabilis
Proteus morganii
Providencia stuartii
Haemophilus influenzae
Bordetella pertussis
Bacteroides corrodens
Yersinia enterocolitica
Brucella species
Klebsiella pneumoniae
Klebsiella oxytoca
Serretia marcescens
Haemophilus parainfluenzae
Bordetella bronchiseptica
Aeromonas hydrophila
Pseudomonas aeruginosa
Pasteurella species
Gram-positive

Flavobacterium species
Staphylococcus aureus
Micrococcus species
Corynebacterium ulcerans
Corynebacterium renale
Corynebacterium ovis
Corynebacterium hofmannii
Staphylococcus epidermidis
Bacillus species
Corynebacterium murium
Corynebacterium equi
Peptostreptococcus asaccharolyticus
Clostridium tetani
Mycobacterium rhodochrous group

Mycoplasma

T-strain mycoplasma
Ureaplasma urealyticum

Yeast

Cryptococcus
Rhodotorula
Sporoblomyces
Candida humicola
Trichosporon cutaneum
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Struvite stones are most commonly observed in patients at higher risk for urinary
infections including females, the elderly, premature infants, and patients with urinary
stasis from urinary tract anomalies, urinary diversions, or neurogenic urinary tract
dysfunction.

1.4.4

Cystine

Cystinuria is an inherited autosomal recessive disorder which results in the excessive
urinary excretion of dibasic amino acids including cystine, lysine, ornithine, and
arginine76. Mutations in the dibasic amino acid transporters SLC3A1 and LSC7A9 result
in impaired proximal tubular reabsorption of cystine, and the poor solubility of cystine
within the urine leads to the formation of cystine stones77,78. The solubility of cystine and
thus the formation of cystine stones depend on multiple factors including cystine
concentration, urine pH, ionic strength, and the presence of macromolecules. However,
because there is no specific inhibitor of cystine crystallization within the urine
supersaturation of cystine and subsequent cystine stone formation occur readily in
physiologic conditions79. Patients with cystinuria typically present early in life and have
multiple episodes of recurrent stone formation.
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1.5

Treatment of Urolithiasis

There exist multiple potential treatment options for stone disease and often the optimal
treatment decision is complex and based on a multitude of patient and stone factors.
Potential treatment strategies can be broadly divided into surgical and non-surgical
options. Non-surgical strategies include active surveillance and expectant management
with or without medical expulsive therapy (MET). Small, non-obstructive, asymptomatic
calyceal stones can be managed conservatively with active surveillance80. In general, the
first line treatment for small ureteric stones is a trial of expectant management as the
majority of these stones will pass spontaneously80. MET with a-blockers or calcium
channel blockers has been shown to increase the likelihood of spontaneous ureteric stone
passage81. Indications for surgical intervention include the presence of infection, an
obstructed solitary kidney or bilateral obstruction, intractable pain or nausea and
vomiting, and failed expectant management.
Surgical treatment options include urinary drainage with a stent or nephrostomy tube,
shockwave lithotripsy (SWL), ureteroscopy, or percutaneous nephrolithotomy (PCNL).
SWL is the procedure with the least morbidity and lowest complication rate; however,
ureteroscopy is associated with a higher stone free rate following a single procedure80.
The efficacy of SWL is dependent on a number of patient and stone factors and has been
demonstrated to be less effective for mid or distal ureteric calculi, larger stones within the
lower pole of the kidney (greater than 1cm), patient obesity, and hard stone compositions
(COM, calcium phosphate, and cystine)80. PCNL is typically reserved for large renal
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stone burdens (greater than 2cm), large lower pole stones with unfavourable anatomy, or
anatomical abnormalities that preclude other treatment options80.
Urolithiasis is a highly recurrent disease and approximately 50% of patients will form a
recurrent stone within ten years of their initial stone episode2. Prevention strategies
include both general dietary and lifestyle recommendations as well as specific medical
prophylaxis based on stone composition and abnormalities identified on in-depth
metabolic evaluations. General lifestyle and dietary measures include increasing fluid
intake to achieve a daily urine output of 2.5L, dietary calcium intake of 1000-1200
mg/day ideally with meals, treatment of documented vitamin D deficiency, moderation of
animal protein intake, avoidance of purine rich foods, limiting daily sodium intake to
1500 mg/day, having a diet rich in fiber, fruits and vegetables, and maintaining a healthy
body weight82. In addition, there are a number of medical therapies which are utilized to
correct specific abnormalities which are identified on a metabolic evaluation. These
medications include thiazide diuretics for the treatment of hypercalciuria, urinary
alkalinization with alkali citrates, xanthine oxidase inhibitors for the treatment of
hyperuricosuria and thiol binding agents for cystine stone formers82. Unfortunately,
current preventative treatment strategies have only resulted in a modest reduction of stone
recurrence rates. In addition, no new therapies for stone prevention have been developed
since the 1980’s when potassium citrate was introduced83. Consequently, an improved
understanding of the pathophysiology behind stone formation is critical in order to allow
for the development of new treatment and prevention strategies.
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1.6

Models of Stone Disease

Despite urinary stone disease being a common condition, which results in significant
patient morbidity and associated health care costs, our understanding of the
pathophysiological mechanisms underlying stone formation remain limited. An
important limitation of stone disease research is the lack of a suitable pre-clinical
research model. The ideal model for investigating urinary stone disease should result in
consistent stone formation and recapitulate the physiology of the human nephron. In
addition, the model should allow for the manipulation of stone formation in order to
investigate potential therapeutic agents. Finally, the model should be simple, practical,
inexpensive, and high-throughput.
Previous animal models of stone disease include murine, canine and porcine models;
however, these all carry significant limitations84-87. The rat model has historically been
the most commonly utilized for studying calcium stone disease. Spontaneous stone
formation does not occur within the rat and must be induced through the administration
of lithogenic agents which produce hyperoxaluria such as sodium oxalate, ammonium
oxalate, hydroxy-L-proline, ethylene glycol and glycolic acid86,88-92. This does not
accurately recapitulate the metabolic milieu present in human urolithiasis where other
metabolic derangements other than hyperoxaluria are present88. In addition, stone
formation in this model occurs in an unpredictable fashion with only a minority of the
experimental animals actually forming stones following a prolonged timeline of up to
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four weeks91,93-96. Many of these lithogenic agents are often nephrotoxic and lead to
renal failure and death of the experimental model97. The majority of the formed calcium
oxalate crystals are non-adherent to the renal epithelium and are washed out in the urine;
this fails to accurately represent stone formation in humans as crystal adherence to the
renal epithelium is a critical initial event and makes measurement of stone deposition
difficult98. The rat model does not allow for live in vivo imaging to visualize stone
burden and the only method to accurately measure stone burden is to sacrifice the animal.
This results in an unnecessary loss of animals, increased costs, and limits the ability to
investigate potential therapeutic targets.
Given the significant costs and resources required for the murine model of stone disease,
larger scale studies are not feasible. Consequently, the majority of previous studies
include small sample sizes which limits the validity of the results. The current available
animal models for urolithiasis have significant limitations which has prompted the
development of newer novel models for stone disease.

1.6.1

Drosophila melanogaster Stone Model

Drosophila melanogaster (DM) has been widely utilized as a versatile model for
numerous human conditions including diabetes and renal disease99,100. The Drosophila
genome is fully sequenced and has been demonstrated to be highly conserved with the
human genome with over 70% of DM genes having human homologs101. Extensive prior
research involving the DM genome has led to the development of exhaustive genome
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databases and microarray expression data102,103. In addition, the DM genome is easily
modifiable using well-established genetic tools making it an invaluable research
model104.
The DM renal system is composed of two components, the nephrocytes and the
Malpighian tubules and functions as a rudimentary human kidney. The nephrocytes are
the functional equivalent of human podocytes within the glomerulus and function to filter
the insect hemolymph105. The DM have four Malpighian tubules, which are divided into
anterior and posterior segments, and join into a common ureter before draining into the
gut at the junction between the mid and hindgut106. The Malpighian tubules serve as the
functional equivalent of the human convoluted tubule have been well characterized in
regard to solute transport and excretion mechanisms106. A diagrammatic comparison of
the human and DM kidney is illustrated in figure 2.

25

Figure 2: Schematic representation of human and Drosophila melanogaster urinary
excretion systems107.
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1.6.2

Crystal Adhesion Assay

The formation of calcium oxalate stones in humans represents a complex and multifactorial metabolic process of which the complete pathophysiology remains unknown.
While animal models are valuable for investigating the overall process of stone formation
and potential therapeutic agents, in vitro models can allow for more specific examination
of the mechanisms involved in stone formation.
Examination of CaOx crystallization, adherence, aggregation, and growth with in vitro
assays have been well utilized to delineate the mechanisms involved in stone
formation108-112. Much of this research has formed our current understanding of the
pathophysiological mechanisms involved in urinary stone disease. While there are
inherent limitations to in vitro models; they can provide a practical, inexpensive and
informative method to investigate mechanistic pathways and examine the interplay
between different factors.
The adherence of CaOx crystals to renal epithelial cells is a critical initial step in the
formation of urinary calculi which allows for further aggregation and growth of the
crystals113. Without this step the crystals would pass through the urinary system without
difficulty113. In vitro assays examining the adherence of CaOx crystals to renal epithelial
cells have previously been developed and utilized to examine stone formation and the
effect of potential stone inhibitors108-113. This assay serves as a useful platform to not
only understand the mechanisms involved but also to identify potential therapeutic targets
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in a high throughput fashion, which can then be further examined with in vivo and human
models.

1.7

Objectives and Aims

Objective 1: Determine whether CaOx stone formation in a Drosophila melanogaster
model is affected by a non-urease producing urinary pathogenic bacterial isolate and/or
by the addition of different antibiotic classes associated with increased human urolithiasis
occurrence.
Epidemiological studies have demonstrated a correlation between both urinary pathogens
and antibiotic exposure on the development of urolithiasis. In order to further examine
potential causation, we investigated the effect of a non-urease producing strain of E. coli
and both ciprofloxacin and trimethoprim-sulfamethoxazole (TMP-SMX) on the
development of CaOx stones in a Drosophila model.
Objective 2: Determine whether CaOx crystal adherence is affected by a non-urease
producing urinary pathogenic bacterial isolate and/or by the addition of different
antibiotic classes associated with increased human urolithiasis occurrence.
In order to further explore potential mechanisms by which both urinary pathogens and
antibiotics may affect stone formation, we will determine the effect of E. coli and both
ciprofloxacin and TMP-SMX on the adherence of CaOx crystals to renal epithelial cells.
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Objective 3: Determine the effect of osteopontin (OPN) on CaOx crystal adherence to
renal epithelial cells.
Osteopontin, a known potent inhibitor of CaOx urolithiasis, has now also been shown to
play an important role in gastrointestinal inflammation and have an inhibitory effect on
endodontic bacteria. Given this, we aimed to further study this urolithiasis-preventing
protein in the context of its influence with the newly described presence of bacteria in the
kidney8, 9. We will determine the effect of E. coli and OPN on the adherence of CaOx
crystals to renal epithelial cells.
Objective 4: Determine the effect of zinc (Zn) chloride on CaOx crystal adherence to
renal epithelial cells.
Given that Zn is known to play a vital role in bacterial pathogenesis and immune
modulation and has also been implicated as an early nidus for the mineralization process
of urinary stones, we would like to further explore its role in the relationship between
urinary bacteria and urolithiasis10, 11, 12. The effect of Zn and E. coli on the adherence of
CaOx crystals to renal epithelial cells will be determined.
Our hypothesis is that urinary bacteria and the antibiotics, ciprofloxacin and
trimethoprim-sulfa methazole, potentiate CaOx stone formation and crystal adhesion by
through the regulation of OPN and Zn transport mechanisms.
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Chapter 2

2

Effect of Antibiotics and a Escherichia coli Urinary
Infection Isolate on Calcium Urolithiasis

Urinary stone disease is a highly prevalent condition with a dramatically rising incidence;
however, the increasing incidence of stone disease has been most pronounced in
populations typically at lower risk for urolithiasis such as women and children. The
cause behind the changing demographics of stone disease has yet to be completely
understood. To further elucidate this, the potential effect of a non-urease producing
bacteria and treatment with antibiotics on the formation of CaOx stones was investigated
in well-established stone models. These included the DM fly model, and an assay of
CaOx crystal adherence to renal epithelial cells1,2.

2.1 Introduction

2.1.1

Urinary Bacteria and Urolithiasis

The casual association between urease-splitting uropathogens and struvite stone
formation is well established. There is increasing evidence that suggests a relationship
between urinary bacteria and the formation of other stone compositions as well. In
epidemiological studies, there is a strong association between culture proven UTIs and
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stone disease, with 28% of patients with stone disease having a history of UTIs2. In the
pediatric population, an association between recurrent UTIs and idiopathic hypercalciuria
has been established3-6. A number of studies have also investigated the impact of the
intestinal microbiota on urinary stone disease; these have demonstrated that the gut
microbiota may be different in stone forming patients, and that the presence of O.
formigenes may reduce stone formation through the degradation of intestinal oxalate7,8.
In addition, bacteria have been identified from stones through both standard culture and
16S rRNA gene sequencing methods9,10. Clinical cultures for bacteria were positive in
44% of pure oxalate stones, with E. coli being the most common organism isolated9,10. It
is suspected, that these results grossly underestimate the presence of bacteria in stones
given that standard culture protocols are not conducive to the growth of more fastidious
bacteria, and that further utilization of 16S rRNA gene sequencing of bacterial DNA will
show a much higher prevalence of bacteria within urinary stones10. Additionally, E. coli
has been shown to promote the aggregation and growth of CaOx crystals11,12. The exact
relationship between urinary bacteria and stone disease has yet to be determined;
however, it has been postulated that bacteria may alter the host inflammatory response
within the kidney thereby potentiating stone formation13.

2.1.2

Antibiotics and Urolithiasis

Several epidemiological studies have correlated urolithiasis with antibiotic exposure in
humans. Multiple studies have demonstrated an association between high rates of
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antibiotic prescriptions and use, with the increased prevalence of stone disease in the
United States14-19. Furthermore, a recent large study examining over 13 million patients
in the United Kingdom revealed a significantly increased risk of the development of
urolithiasis following exposure to a number of antibiotic classes including sulfa,
cephalosporin, fluoroquinolone, nitrofurantoin, and penicillin20. The increased risk
following exposure to sulfa and fluoroquinolone was especially striking with odds ratios
of 2.37 and 1.84 respectively19. In addition, they also observed a higher risk of stone
disease with more recent antibiotic exposure and exposure at younger ages20
It has been postulated that antibiotic use results in disruption of the microbiota and
subsequent metabolic dysfunction and stone formation. This is supported by previous
investigation which has demonstrated that antibiotic therapy for both cystic fibrosis and
H. pylori infection resulted in decreased rates of O. formigenes colonization and higher
urinary oxalate levels21,22. The negative impact of antibiotic exposure on urinary stone
risk is further supported by a recent study which observed a four-time higher risk of
urolithiasis in children with asthma, a condition associated with frequent childhood
antibiotic exposure23. Furthermore, a mouse study which modeled pediatric antibiotic
exposure demonstrated an altered host microbiota, decreased oxalate metabolism genes
and fecal oxalate levels; further supporting that antibiotic exposure may potentiate stone
formation through alteration of the microbiota24.
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2.2 Methods

This study did not require ethics approval from the University of Western Ontario’s
animal use subcommittee as the experimental use of the invertebrate DM flies are
currently exempt.

2.2.1

2.2.1.1

Drosophila melanogaster Stone Model

Fly Husbandry

Canton-S wildtype flies (Stock #64349) were utilized for all experiments and were
sourced from Bloomington Stock Center, Indiana, USE (hht://fly.bio.indiana.edu). All
fly stocks were housed in wide fly vials within pre-divided trays (Genesee Scientific
Corporation, CA). All DM flies were maintained in a dedicated Drosophila incubator
(DigiThermâ Drosophila Incubator, Tritech Research Inc.) under standard conditions at
25°C with 40% humidity and a 12/12hr light/dark cycle. All fly stocks were inspected
for signs of bacterial, fungal and mite infestation on a daily basis. Stocks were
transferred to fresh food media every 3-4 days or earlier based on experiment timing in
order to prevent contamination, allow for an adequate supply of media, and reduce the
presence of larvae.
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2.2.1.2

Preparation of Food Media

Food media was prepared on a monthly basis in order to avoid contamination and ensure
appropriate freshness. The media was prepared manually in 1-liter batches. All the
media ingredients were weighed with a digital scale (Sartorius AG, Goettingen,
Germany), mixed with distilled water and heated into solution with a standard laboratory
hot plate (Salton Appliances Corp., Dollard Des Ormeaux, Canada). The prepared media
was then aliquoted into wide polypropylene fly vials (GEN32-121, Genesee Scientific,
California, USA) and cooled for 8-12 hours at room temperature covered with grade 50
cheesecloth (GEN53-100, Geness Scientific, California, USA) in order to allow for
adequate solidification of the media. The vials were then closed with dense cellulose
acetate plugs (49-101 Diamed Inc., Mississauga, Canada) and stored at 4°C in a humidity
controlled cold room. Food media was discarded after a period of one month if it was
unused.

2.2.1.2.1

Standard Food Media

Standard food media was prepared according to the standard Bloomington stock center
recipe (BDSC Cornmeal Food, Bloomington Stock Centre, Indiana IN). This media
formulation results in firm media which resists liquefaction from larval burrowing. The
ingredients used to prepare a 1-liter batch of food are listed in table 3.
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Table 3: Ingredients for preparation of standard Drosophila melanogaster food
media.
Ingredient

Product Number

Distilled water

-

Drosophila agar

66-103 Diamed Inc.

5.7 g

Inactive yeast

62-106 Diamed Inc.

19.3 g

Soy flour

62-115 Diamed Inc.

10 g

Yellow corn meal

62-100 Diamed Inc.

73 g

Light corn syrup

62-117 Diamed Inc.

75 ml

Propionic acid

1368 Sigma Inc.

1.25 ml

Phosphoric acid

290017 Sigma Inc.

3.75 ml

Amount
1000 ml
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To prepare the media, 700ml distilled water was boiled and the agar was added in small
amounts until completely dissolved. Proper cooking of the agar allowed for improved
solidification of the food media within the fly vials. Following this, the yeast, soy flour,
and corn meal were added to the solution and simmered for 10 minutes at medium heat.
The remaining 300 ml of distilled water was mixed with the corn syrup and added to the
solution where it was simmered for an additional 5 minutes. The acid mix was the added
to inhibit bacterial and fungal growth. The solution was then cooled to 60°C and
dispensed to the fly vials.

2.2.1.2.2

Lithogenic and Antibiotic Food Media

To induce CaOx stone formation within the DM flies a lithogenic diet containing 0.1%
w/v sodium oxalate (NaOx; 71800 Sigma Inc., Oakville, Canada) was utilized. Previous
analysis with scanning electron microscopy and energy dispersive x-ray spectroscopy has
demonstrated that a lithogenic diet with NaOx results in the formation of COM
(whewellite) and COD (weddellite) crystals similar to those observed in human urinary
stone disease25.
Administration of sub-inhibitory antibiotic treatment to the DM flies also occurred
through the addition of the antibiotic to the food media. Ciprofloxacin (17850 Sigma
Inc., Oakville, Canada) or TMP-SMX (A2487 Sigma Inc., Oakville, Canada) was added
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to either the standard or lithogenic media at a concentration of 0.2 μg/mL or 30/10 μg/mL
respectively. All agents were thoroughly dissolved in distilled water prior to being added
to the food media recipe described above.

2.2.1.3

Inoculation with Escherichia coli

A non-urease producing strain of E. coli UTI89 (E. coli Genetic Stock Center, New
Haven, United States) isolated from a human UTI was utilized to inoculate wild-type
Canton-S DM flies. A single colony of UTI89 was used to inoculate 25ml of lysogeny
broth (LB, 10855001, Fisher Scientific Inc., Ottawa, Canada) in a 50ml conical falcon
tube (14-432-22, Fisher Scientific Inc., Ottawa, Canada) and incubated for 12 hours at
37°C. Following this the UTI89 was pelleted by centrifuging the inoculated LB at 5000
rpm for 5 minutes and the supernatant was decanted. The UTI89 pellet was then
reconstituted in 1ml of 5% sucrose solution. 10μl aliquots of the UTI89 solution were
then placed on top of the DM media, spread evenly over the surface with a sterile cell
scraper (179693, Fisher Scientific Inc., Ottawa, Canada), and allowed to dry. Control
groups were treated with 10μl of 5% sucrose solution without UTI89 using the same
technique. Fresh UTI89 or control 5% sucrose was added to the media daily.
Inoculation with UTI89 was confirmed by culturing sterilized DM flies following
exposure to the bacteria. DM flies were exposed to UTI89 as described above for 24
hours and then transferred to standard food media without bacteria. Flies were then
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euthanized every 24 hours with carbon dioxide (CO2) for a period of three days. The
external surface of the fly was sterilized with 70% ethanol (Sigma Inc., Oakville,
Canada). The DM fly was then pulverized in 50μl of phosphate buffered solution (PBS)
with 0.5mm glass beads (Z250465, Sigma Inc., Oakville, Canada) utilizing the mini bead
beater mill (RK-36270-02, Cole-Parmer, Montreal, Canada). 10μl of the pulverized DM
fly solution was plated on an LB agar plate (2270025, Fisher Scientific Inc., Ottawa,
Canada) and incubated for 12 hours at 37°C. Colony counts per fly were then determined
per standard methods. Escherichia coli UTI89 was cultured at a minimum concentration
of 3x103 colony forming unit (CFU) per fly for up to three days following the 24-hour
exposure with UTI89. Control flies did not demonstrate any bacterial growth and no
other strains of bacteria were cultured from the DM flies.

2.2.1.4

Age and Sex Matching

In order to ensure that all adult flies utilized in all the experiments were of the same age
and health, wild type Canon-S were age and sexed matched. Approximately 100-150
wild-type Canton-S DM flies were isolated in a 6oz square bottom bottle (GEN32-130,
Diamed Inc., Mississauga, Canada) with standard food media along with a 1cm wide
aliquot of active yeast paste (62-103 Diamed Inc., Mississauga, Canada) and grape juice
agar. The active yeast and grape juice agar stimulated mating and provided additional
nutrition. Mating and egg deposition occurred for 24 hours and following this the adult
flies were removed. The eggs were then allowed to eclose and age matched adult flies
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were collected after 4 days and sorted according to gender. The flies were sorted by
gender following CO2 narcotization on the fly pad (Flystuff Inc., San Diego, United
States). The age and sex matched adult flies were then utilized in all the experiments.

2.2.1.4.1

Preparation of Grape-Juice Agar Plates

Grape-juice agar was prepared in 500ml batches on a monthly basis using the ingredients
listed in table 4. The agar and sucrose were added to the distilled water and heated until
completely dissolved. The grape-juice concentrate was the added and thoroughly mixed.
The solution was then cooled to 60°C and the ethanol and glacial acetic acid was added in
order to inhibit bacterial and fungal growth. The solution was then aliquoted into 100mm
plastic petri dishes (VWR Inc., Radnor, United States) and solidified at room
temperature. The plates were stored at 4°C in a humidity controlled cold room and
discarded after a month if unused.
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Table 4: Ingredients for preparation of grape-juice agar plates.
Ingredient

Product Number

Amount

Distilled water

-

375 ml

Bacteriological agar

5306 Sigma Inc.

12 g

Sucrose

7903 Sigma Inc.

22 g

Grape juice

Welch’s grape-juice concentrate

110 ml

Ethanol

Sigma Inc.

10 ml

Glacial acetic acid

2183 Sigma Inc.

5 ml
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2.2.1.5

Lifespan Studies

Fifty age and sex matched wild type Canton-S flies were anesthetized with CO2
narcotization and added to either standard media or lithogenic food media with or without
E. coli UTI89. Three separate replicates were performed for every treatment group.
UTI89 or sucrose control was added to the media daily as described above. Fly media
was exchanged every 3 days to avoid competition for fresh food which could potentially
impact survival. DM fly deaths were recorded daily, and any flies lost during transfer
were censored. The adult flies were followed until the last death.

2.2.1.6

Calcium Oxalate Stone Formation in Drosophila
melanogaster Following Exposure to Escherichia coli and
Antibiotics

Thirty age and sex matched wild type Canton-S flies were added to wide vials containing
either standard or lithogenic food media with or without E. coli UTI89 exposure for
either a 7- or 14-day assay. Treatment with ciprofloxacin (0.2 μg/mL) or TMP-SMX
(30/10 μg/mL) occurred on day 5-7 of the assay. Following completion of the assay the
DM flies were removed, euthanized and processed for imaging. Three separate replicates
were performed for each of the different treatment groups and assay timelines. A
schematic of the various treatment groups is presented in figure 3.
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Figure 3: Schematic representation of treatment groups in Drosophila melanogaster
fly model.

50

2.2.1.6.1

Dissection of Drosophila melanogaster Malpighian
Tubules

Malpighian tubules were dissected from DM flies immediately following euthanization
with CO2. Dissections were performed under a dissecting light microscope (AmScope
Inc., Irvine, United States) on a culture dish in Schneider’s Drosophila medium (0146
Sigma Aldrich Inc., Oakville, Canada) utilizing fine forceps (Fine Science Tools Inc.,
Vancouver, Canada). Schneider’s Media was selected as a dissection medium as its
composition most closely resembles insect hemolymph and prevents osmotic cell lysis.
Dissections were carried out in a Sylgard lined Pyrex Petri dish (3160100 Sigma Aldrich
Inc., Oakville, Canada) to provide additional protection to the delicate DM tissues. A
minimal touch technique was utilized where the DM fly was anchored with forceps at the
superior aspect of the thorax. The anal region or Terminalia of the DM fly was then
grasped with forceps and the hindgut was removed with gentle pressure. Following the
hindgut, the anterior and posterior tubules emerged. The midgut was then severed, and
the fly was discarded.
The dissected Malpighian tubules were then fixed in 4% formaldehyde (252549, 0146
Sigma Aldrich Inc., Oakville, Canada) in PBS for 1 hour and mounted on a frosted
microscope slide (510D, Fisher Scientific Inc., Ottawa, Canada) in 50% glycerol (G5516,
0146 Sigma Aldrich Inc., Oakville, Canada) in PBS with a 22mm glass coverslip (3400,
Fisher Scientific Inc., Ottawa, Canada). The edges of the coverslip were sealed with
clear nail polish. Birefringent microscopy images of CaOx crystals within dissected
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Malpighian tubules were obtained with an inverted light microscope (Nikon Inc., Tokyo,
Japan) with a 100x magnification.

2.2.2

2.2.2.1

Calcium Oxalate Crystal Adherence

Cell Culture

Madin-Darby Canine Kidney (MDCK) renal epithelial cells (ATCC-CCL-34, NBL-2,
Manassas, VA) were utilized for the crystal adherence assay. A stock of MDCK cells
was cultured in T75 cell culture flasks (156499, Fisher Scientific Inc., Ottawa, Canada) at
37°C in 5% CO2 utilizing a Forma Steri-Cycle CO2 incubator (370, Fisher Scientific Inc.,
Ottawa, Canada). The MDCK cells were cultured in Dulbecco’s Modified Eagle’s
medium (DMEM; Thermo Fisher Scientific, Waltham, MA) supplemented with 10%
fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA). No antibiotic
additives were included in the cell media. The MDCK cells were cultured to 90%
confluence and then passaged onto 150 mm cell culture plates (172931, Thermo Fisher
Scientific, Waltham, MA) at a concentration of 5.0x106 cells per plate. In order to
passage the cells onto the cell culture plates, the adherent cells were incubated with 0.5%
trypsin (15400054, Thermo Fisher Scientific, Waltham, MA) for 10 minutes to allow for
cell detachment. The detached cells were the centrifuged at 1000 rpm for 5 minutes at
37°C in a 15 ml conical falcon tube (T1943, Sigma Aldrich Inc., Oakville, Canada). The
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cell pellet was the resuspended in 2 ml of cell media and cell concentration was
determined with a hemocytometer. Cell media was exchanged every three days and cells
were inspected under the microscope to ensure viability. MDCK cells were used until a
maximum passage of ten and then exchanged for a fresh stock. Once cells reached 90%
confluence on the 150mm cell culture dishes they were utilized for the crystal adherence
assay.

2.2.2.2

Crystal Adherence Assay

In order to conduct the crystal adherence assay, MDCK cells were grown to 90%
confluence in 150mm cell culture dishes. The MDCK cells were then exposed to E. coli
UTI89 at a concentration of 103 CFU suspended in standard cell culture media for 20
minutes at 37°C. The UTI89 was then removed by gently washing the MDCK cells with
5ml of fresh cell culture media twice. Following this, the MDCK cells were incubated
with CaOx crystal suspension (0.5 mg/mL; 455997, Sigma Aldrich Inc., Oakville,
Canada) in artificial urine with or without the addition of ciprofloxacin (0.2 μg/mL) or
TMP-SMX (30/10 μg/mL) for an additional 20 minutes. The artificial urine was
prepared with the ingredients listed in table 5 according to the protocol previously
described26. The properties of the artificial urine are listed in table 6. Once again, the
MDCK cells were gently washed with cell culture media twice in order to remove any
unattached crystals. Fresh cell culture media was then replaced, and the cells were
immediately imaged with birefringent microscopy utilizing an inverted light microscope
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(Nikon Inc., Tokyo, Japan) under a 100x magnification prior to cell death occurring.
Five separate cell culture dishes per treatment group were utilized for the experiment, and
three separate replicates of all treatment groups were performed.
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Table 5: Ingredients for the preparation of artificial urine26.
Ingredient

Amount

Urea

2.427 g

Uric acid

0.034 g

Creatinine

0.090 g

Na3C6H507×2H20

0.297 g

NaCl

0.634 g

KCl

0.450 g

NH4Cl

0.161 g

CaCl2×2H20

0.089 g

MgS04×7H20

0.100 g

NaHC03

0.034 g

NaC204

0.003 g

Na2S04

0.258 g

NaH2P04×H20

0.100

Na2HP04

0.011 g

Deionized water

200 ml
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Table 6: Properties and compositions of artificial urine26.
Property and Composition
pH
Specific gravity
Osmolality

Concentration
6.2
1.010 g/ml
446 mOsm/kg

Urea

200 mM

Uric acid

1.00 mM

Creatinine

4.00 mM

Na3C6H507

5.00 mM

NaCl

54.00 mM

KCl

30.00 mM

NH4Cl

15.00 mM

CaCl2

3.00 mM

MgS04

2.00 mM

NaHC03

2.00 mM

NaC204

0.10 mM

Na2S04

9.00 mM

NaH2P04

3.60 mM

NaHP04

0.40 mM
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2.2.3

Data Analysis

Pixel intensity of birefringent CaOx crystals were quantified utilizing MATLAB
(MathWorks, 2018) using a threshold pixel intensity of 150. For processing of the
dissected Malpighian tubules only the tubules of interest were outlined and included
within the analysis. Background pixel intensity was subtracted for all image analysis.
Statistical analysis was performed with SPSS version 25.0 (IBM, New York, USA) using
a one-way analysis of variance (ANOVA) with a p value of <0.05. For survival curve
analysis the log-rank test was used to determine the significance of change.

2.3 Results

2.3.1
2.3.1.1

Drosophila melanogaster Model
Drosophila melanogaster Survival with Lithogenic Diet and
Escherichia coli Exposure

Treatment of DM flies with E.coli did not affect fly survival, and both control and UTI89
treated flies survived for a median of 33 days on standard food media. This effect was
consistent in flies fed a lithogenic diet, with the oxalate control and oxalate with UTI89
DM flies surviving a median of 23 and 24 days respectively. The mean and median
survival time is summarized in table 7. However, treatment with the lithogenic diet
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resulted in significantly reduced survival time compared with DM flies fed a standard
diet (p<0.0001, table 8). A Kaplan-Meier curve comparing survival among different
treatment groups is illustrated in figure 4.
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Table 7: Mean and median survival of Drosophila melanogaster following treatment
with sodium oxalate (0.1%) or Escherichia coli UTI89. Estimation is limited to the
largest survival time if it is censored, (n=150/group).
Treatment

Control
UTI89
Oxalate Control
Oxalate with UTI89

Est.
30.174
29.807
21.461
22.279

Mean
95% Confidence Interval
Std. Error
Lower
Upper
1.503
27.229
33.120
1.584
26.701
32.912
1.162
19.184
23.737
1.123
20.594
24.996

Est.
33.000
33.000
23.000
25.000

Median
95% Confidence Interval
Std. Error
Lower
Upper
0.801
31.430
34.570
1.226
30.597
35.403
2.098
18.888
27.112
.983
25.074
28.926

Table 8: Statistical analysis of the survival distribution of Drosophila melanogaster
following treatment with sodium oxalate (0.1%) or Escherichia coli UTI89,
(n=150/group).
Chi-Square

df

Sig.

Log Rank (Mantel-Cox)

33.557

3

0.000

Breslow (Generalized Wilcoxon)

12.380

3

0.006

Tarone-Ware

21.446

3

0.000
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Figure 4: Kaplan Meier survival analysis of Drosophila melanogaster following
exposure to sodium oxalate (0.1%) lithogenic diet or Escherichia coli UTI89
(n=150/group).
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2.3.1.2

2.3.1.2.1

Calcium Oxalate Stone Formation in Drosophila
melanogaster Malpighian Tubules

Calcium Oxalate Stone Formation in Drosophila
melanogaster Malpighian Tubules following
Escherichia coli Exposure: A Timed Analysis

To assess for appropriate time points for the treatment assays, wild-type Canton-S DM
were exposed to either a standard or lithogenic diet with 0.1% NaOx for 21 days with or
without the addition of E. coli UTI89. Malpighian tubules were dissected and analyzed
for CaOx crystal deposition at days 7, 14, and 21 under a birefringent light microscope.
DM flies fed the standard diet did not form any CaOx crystals within the dissected
Malpighian tubules. Representative images of the CaOx crystals within the dissected
Malpighian tubules at the different timepoints are shown in figure 5.
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Figure 5: Calcium oxalate stone formation in dissected Malpighian tubules following
exposure to standard diet of sodium oxalate (0.1%) lithogenic diet with or without
Escherichia coli UTI89 at days 7, 14, and 21 under 100x magnification.
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Comparisons between the oxalate control tubules demonstrated increasing amounts of
CaOx crystal deposition with longer exposure to the lithogenic diet as would be expected.
The amount of CaOx crystal deposition appeared to plateau around the 21-day time point
and was consistent with the median survival time for the DM flies fed the lithogenic
media. In addition, exposure of the DM flies to E. coli UTI89 appeared to increase CaOx
crystal deposition at the day 7 and 14 timepoints; however, the difference was less
striking at the later 14-day timepoint. There did not appear to be any difference in CaOx
crystal deposition between the oxalate control and oxalate with UTI89 treatment group at
the latest 21-day timepoint. Given this data, a 7- and 14-day assay time period was
selected for the remainder of the experiments.

2.3.1.2.2

Calcium Oxalate Stone Formation in Drosophila
melanogaster Malpighian Tubules Following
Escherichia coli Exposure

Inoculation of DM flies with E. coli UTI89 was observed to significantly increase CaOx
stone formation within dissected Malpighian tubules following 7 days of exposure
(p=0.005); however, there was no difference noted in stone formation with the longer 14day treatment period. Representative images of the CaOx crystals within the dissected
Malpighian tubules are shown in figure 6. The mean measured pixel intensity of the
CaOx crystals within the tubules stratified by treatment group is displayed in figure 7.
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Figure 6: Representative birefringence microscopy images of calcium oxalate stone
formation in dissected Malpighian tubules following exposure to sodium oxalate
(0.1%) lithogenic diet with or without Escherichia coli UTI89 at days 7 and 14 under
100x magnification.
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Figure 7: Measured pixel intensity of calcium oxalate stone formation in dissected
Malpighian tubules following exposure to sodium oxalate (0.1%) lithogenic diet with
or without Escherichia coli UTI89 at days 7 and 14. Data displayed as mean ± SEM
(n=29-80/group), *p<0.05 compared with day 7 oxalate control.
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2.3.1.2.3

Calcium Oxalate Stone Formation in Drosophila
melanogaster Malpighian Tubules Following Antibiotic
Treatment

Wild-type Canton-S DM flies were observed to have significant increases in CaOx stone
burden following exposure to both ciprofloxacin (0.5μg/mL; p<0.001) and TMP-SMX
(30/10 μg/mL; p<0.001) at the 7-day time point. In addition, CaOx crystal deposition
was noted to further increase in both groups at the 14-day time point (p<0.05). This is
interesting given that the actual antibiotic treatment duration and time points were the
same for both the 7- and 14-day assays; with the DM flies only being exposed to
antibiotics on days 5-7 of each assay. Comparatively, TMP-SMX exhibited a trend
towards greater CaOx stone formation compared with ciprofloxacin; however, this was
not statistically significant. Representative microscopy images of the CaOx crystals
within the dissected Malpighian tubules are displayed in figure 8. The mean measured
pixel intensity of the CaOx crystals within the tubules stratified by treatment group is
demonstrated in figure 9.
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Figure 8: Representative birefringence microscopy images of calcium oxalate stone
formation in dissected Malpighian tubules following exposure to sodium oxalate
(0.1%) lithogenic diet with or without ciprofloxacin (0.2 µg/mL) or trimethoprimsulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7 and 14 under 100x
magnification.
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Figure 9: Measured pixel intensity of calcium oxalate stone formation in dissected
Malpighian tubules following exposure to sodium oxalate (0.1%) lithogenic diet with
or without ciprofloxacin (0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMPSMX; 30/10 µg/mL) at days 7 and 14. Data displayed as mean ± SEM (n=2980/group), *p<0.05 compared with day 7 oxalate control, #p<0.05 compared with
day 14 oxalate control.
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2.3.1.2.4

Calcium Oxalate Stone Formation in Drosophila
melanogaster Malpighian Tubules Following
Combination Treatment with Escherichia coli UTI89
and Antibiotics

In order to further investigate the potential interaction between urinary pathogens and
antibiotic exposure, DM flies were co-treated with a combination of UTI89 and either
antibiotic. It was observed that co-treatment of the DM flies with both E. coli UTI89
and either antibiotic had no overall effect on stone burden for both measured time points
at day 7 and 14. The combination of the E. coli and antibiotic appeared to negate each
other’s effects and the overall stone burden was not observed to be any different
compared to the oxalate control group. For comparison purposes representative
microscopy images of the CaOx crystals within the dissected Malpighian tubules for all
the treatment groups including the combination treatment are displayed in figure 10. In
addition, the mean measured pixel intensity of the CaOx crystals within the tubules
stratified by treatment group is shown in figure 11. Details of the ANOVA statistical
analysis for all group comparisons are summarized in tables 9-11.
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Figure 10: Representative birefringence microscopy images of calcium oxalate stone
formation in dissected Malpighian tubules following exposure to sodium oxalate
(0.1%) lithogenic diet with or without Escherichia coli UTI89, ciprofloxacin (0.2
µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7 and

14 under 100x magnification.
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Figure 11: Measured pixel intensity of calcium oxalate stone formation in dissected
Malpighian tubules following exposure to sodium oxalate (0.1%) lithogenic diet with
or without Escherichia coli UTI89, ciprofloxacin (0.2 µg/mL) or trimethoprimsulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7 and 14. Data displayed as
mean ± SEM (n=28-80/group), * p<0.05 compared with day 7 oxalate control,
#p<0.05 compared with day 14 oxalate control.
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Table 9: Mean measured pixel intensity of calcium oxalate stone formation in
dissected Malpighian tubules following exposure to sodium oxalate (0.1%)
lithogenic diet with or without Escherichia coli UTI89, ciprofloxacin (0.2 µg/mL) or
trimethoprim-sulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7 and 14.
Day 7
Oxalate Control
Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

N
79
40
48
69
30
51

Mean
0.0410
0.1100
0.0978
0.0719
0.0554
0.0652

SD
0.06931
0.13704
0.13873
0.06000
0.07143
0.07979

Std. Error
0.00780
0.02167
0.2002
0.00722
0.01304
0.01117

Day 14
Oxalate Control
Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

42
69
68
28
63
47

0.0626
0.1341
0.1833
0.0549
0.0517
0.0590

0.05225
0.12509
0.18707
0.03064
0.11503
0.07695

0.00806
0.01506
0.02269
0.00579
0.01449
0.01122

95% CI
Lower
Upper
0.0255
0.0566
0.0662
0.1539
0.575
0.1381
0.0575
0.0863
0.0287
0.0821
0.0428
0.0877

0.0463
0.1041
0.1380
0.0431
0.0227
0.0364

0.0789
0.1642
0.2286
0.0668
0.0807
0.0816

Table 10: ANOVA analysis of mean measured pixel intensity of calcium oxalate
stone formation in dissected Malpighian tubules following exposure to sodium
oxalate (0.1%) lithogenic diet with or without Escherichia coli UTI89, ciprofloxacin
(0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7
and 14.
Sum of Squares

df

Mean Square

Between Groups

1.215

11

0.110

Within Groups

7.361

622

0.012

Total

8.577

633

F

Sig.

9.337 0.000
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Table 11: ANOVA analysis with Tukey post-hoc analysis for multiple group
comparison of mean measured pixel intensity of calcium oxalate stone formation in
dissected Malpighian tubules following exposure to sodium oxalate (0.1%)
lithogenic diet with or without Escherichia coli UTI89, ciprofloxacin (0.2 µg/mL) or
trimethoprim-sulfamethoxazole (TMP-SMX; 30/10 µg/mL) at days 7 and 14.
95% CI
Lower
Upper

Mean Difference

Std. Error

Sig.

Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

-0.09311
-0.14227
-0.6901
-0.01436
-0.02421

0.01793
0.01800
0.02111
0.02333
0.01954

0.000
0.000
0.005
1.000
0.986

-0.1519
-0.2013
-0.1383
-0.0710
-0.0883

-0.0343
-0.0832
0.0002
0.0496
0.00399

Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

-0.07156
-0.12072
0.00765
0.01089
0.00362

0.02129
0.02135
0.02654
0.02167
0.02310

0.039
0.000
1.000
1.000
1.000

-0.1414
-0.1908
-0.0792
-0.0602
-0.0722

-0.0017
-0.0507
0.0605
0.0820
0.0794

Group Comparison
Day 7
Oxalate Control

Day 14
Oxalate Control
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2.3.2

Calcium Oxalate Crystal Adherence Assay

2.3.3

Calcium Oxalate Crystal Adherence to Renal Epithelial Cells
Following Escherichia coli Exposure

To further evaluate the potential mechanism that urinary pathogens may alter stone
formation, renal epithelial cells were exposed to a non-urease producing strain of E. coli
and adherence of CaOx crystals was measured. Exposure of MDCK renal epithelial cells
to E. coli UTI89 was observed to result in a significant increase in CaOx crystal
adherence compared to control (p=0.001). This correlated with the results observed in
the DM fly model where UTI89 exposure was also observed to increase CaOx stone
burden. Representative birefringent microscopy images of the CaOx crystals adhered to
the MDCK cells are displayed in figure 12. The mean measured pixel intensity of the
CaOx crystals stratified by treatment group is displayed in graphical form in figure 13.
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Figure 12: Representative birefringence microscopy images of calcium oxalate
crystal adherence to MDCK renal epithelial cells following exposure to Escherichia
coli UTI89 (103 CFU) under 100x magnification.
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Figure 13: Measured pixel intensity of calcium oxalate crystal adherence to MDCK
renal epithelial cells following exposure to Escherichia coli UTI89 (103 CFU). Data
displayed as mean ± SEM (n=15/group), * p<0.05 compared with control.
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2.3.3.1

Calcium Oxalate Crystal Adherence to Renal Epithelial
Cells Following Treatment with Antibiotics

Exposure of the MDCK renal epithelial cells to the two different antibiotic classes had
differing treatment effects. Treatment of MDCK cells with ciprofloxacin was observed
to increase CaOx crystal adhesion (p<0.001). Whereas, treatment with TMP-SMX did
not appear to significantly alter crystal adhesion compared to the control. This is in
contrast to the results observed in the DM fly model where both antibiotic classes were
observed to significantly increase stone formation within the Malpighian tubules.
Representative microscopy images of CaOx crystal adherence to the MDCK cells are
shown in figure 14 and the mean measured pixel intensity of the CaOx crystals stratified
by treatment group is displayed in figure 15.

77

Figure 14: Representative birefringence microscopy images of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with
ciprofloxacin (0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX; 30/10
µg/mL) under 100x magnification.
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Figure 15: Measured pixel intensity of calcium oxalate crystal adherence to MDCK
renal epithelial cells treated with ciprofloxacin (0.2 µg/mL) or trimethoprimsulfamethoxazole (TMP-SMX; 30/10 µg/mL). Data displayed as mean ± SEM
(n=15/group), * p<0.05 compared with control.
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2.3.3.2

Calcium Oxalate Crystal Adherence to Renal Epithelial
Cells Following Combination Treatment with Escherichia
coli and Antibiotics

Once again, in order to further evaluate the potential interaction between urinary
pathogens and antibiotic exposure, MDCK cells were exposed to a combination of UTI89
and either antibiotic treatment. MDCK cells treated with the combination of UTI89 and
either antibiotic were shown to have no difference in adherence of CaOx crystals
compared to the control. This was very similar to the results observed in the DM fly
model were the combination of urinary pathogen exposure and antibiotic treatment
appeared to negate each other’s effect and result in no overall difference in stone burden.
For comparison purposes representative microscopy images of CaOx crystal adherence to
MDCK cells for all the treatment groups including the combination treatment are
displayed in figure 16. In addition, the mean measured pixel intensity of the CaOx
crystals stratified by treatment group is shown in figure 17. Details of the ANOVA
statistical analysis for all group comparisons are summarized in tables 12-14.
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Figure 16: Representative birefringence microscopy images of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with or
without Escherichia coli UTI89 (103 CFU), ciprofloxacin (0.2 µg/mL) or
trimethoprim-sulfamethoxazole (TMP-SMX; 30/10 µg/mL) under 100x
magnification.
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Figure 17: Measured pixel intensity of calcium oxalate crystal adherence to MDCK
renal epithelial cells following treatment with or without Escherichia coli UTI89 (103
CFU), ciprofloxacin (0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX;
30/10 µg/mL). Data displayed as mean ± SEM (n=15/group), * p<0.05 compared
with control.
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Table 12: Mean measured pixel intensity of calcium oxalate crystal adherence to
MDCK renal epithelial cells following treatment with or without Escherichia coli
UTI89, ciprofloxacin (0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX;
30/10 µg/mL).

Oxalate Control
Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

N
15
15
15
15
15
15

Mean
86039.9
352201.8
144028.6
195313.2
122517.0
123983.9

SD
46463.8
94654.6
86535.8
51780.0
83892.1
40721.6

Std. Error
11996.9
24439.7
22343.4
13369.5
21660.8
10514.3

95% CI
Lower
Upper
60309.1 30932.0
299783.8 404619.8
96106.7 191950.5
166638.4 223988.1
76059.1 168974.9
101433.0 146534.7

Table 13: ANOVA analysis of mean measured pixel intensity of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with or
without Escherichia coli UTI89, ciprofloxacin (0.2 µg/mL) or trimethoprimsulfamethoxazole (TMP-SMX; 30/10 µg/mL).
Sum of Squares

df

Mean Square

Between Groups

6.890E+11

5

1.378E+11

Within Groups

4.198E+11

84

4.997E+9

Total

1.109E+12

89

F

Sig.

27.573 0.000
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Table 14: ANOVA analysis with Tukey post-hoc analysis for multiple group
comparison of mean measured pixel intensity of calcium oxalate crystal adherence
to MDCK renal epithelial cells following treatment with or without Escherichia coli
UTI89, ciprofloxacin (0.2 µg/mL) or trimethoprim-sulfamethoxazole (TMP-SMX;
30/10 µg/mL).
Mean Difference

Group

Sig.

Error

Comparison
Oxalate
Control

Std.

95% CI
Lower
Upper

Cipro
TMP-SMX
UTI89
UTI89 with Cipro
UTI89 with TMP-SMX

-266161.9
-57988.7
-109273.4
-36477.1
-37944.0

25813.05
85601.0
30932.0
13141.0
95406.0

0.000
.228
0.001
0.719
0.684

-341446.8
-133273.6
-184558.3
-111762.0
-113228.9

190877.0
17296.2
-33988.5
38807.8
37340.9
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2.4 Discussion

The results of our study provide evidence that both a urinary pathogen and antibiotics
may have a causal role in the development of calcium urolithiasis. Exposure to a nonurease producing strain of E. coli was demonstrated to increase both CaOx crystal
adherence and stone burden in DM Malpighian tubules. However, the overall stone
burden was only significantly increased at the day 7 time point but failed to show a
persistent elevation at the later 14-day time point. This may suggest that the impact of E.
coli on stone formation is transient and can be further propagated or ameliorated
depending on other conditions. Further investigation will be required in order to
delineate the potential influence of other factors such has the duration, severity, and
virulence of the E. coli infection, and other factors such as antibiotic exposure and
composition and resilience of the microbiota.
Antibiotic exposure of DM flies with both ciprofloxacin and TMP-SMX was observed to
have an even greater effect on stone formation than inoculation with E. coli. In addition,
the effect of both antibiotics on stone burden was further increased at the later 14-day
time point compared to the 7-day time point, demonstrating that antibiotic exposure had a
durable long-lasting effect. TMP-SMX demonstrated a trend towards increased stone
formation compared with ciprofloxacin, which is consistent with previous human
epidemiological studies which demonstrated a higher relative risk of stone formation with
TMP-SMX compared with ciprofloxacin20. Interestingly, treatment of MDCK cells with
ciprofloxacin significantly increased CaOx crystal adherence; however, this same effect
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was not demonstrated with TMP-SMX exposure. This suggests that both TMP-SMX and
ciprofloxacin may be increasing stone formation through different mechanisms.
The observed effect of both ciprofloxacin and TMP-SMX on stone formation are striking
given that DM flies were only exposed to a sub-inhibitory concentration of antibiotics
over a short 3-day course on days 5-7 during both the 7 and 14-day assays. Sub-inhibitory
concentrations of antibiotics were utilized in this study as it was thought this may further
increase the effect of E. coli infection on stone formation. This was based on previous
evidence which demonstrated that sub-inhibitory concentrations of antibiotics can
potentiate bacterial virulence28. Further investigation with alternate concentrations and
durations of antibiotic exposure may help to define the effect of antibiotics on stone
formation.
Exposure of both DM flies and MDCK cells to a combination of both E. coli UTI89 and
either ciprofloxacin or TMP-SMX failed to demonstrate a difference in both CaOx crystal
adhesion and stone formation. This suggests that antibiotic exposure may only potentiate
stone formation in the absence a urinary pathogen. Based on our data, it appears as
though antibiotic exposure has a more profound effect on stone formation compared to
urinary pathogen exposure. Stone formation following antibiotic exposure was observed
to be significantly higher and result in a more durable effect than treatment with E. coli.
This is consistent with epidemiological data which has demonstrated correlations
between higher antibiotic use and the increasing prevalence of urolithiasis. This also
suggests stone formation in humans may occur from antibiotics that are prescribed for
non-urinary infections or when the duration of antibiotic treatment surpasses the presence
of the urinary pathogen. This may have particular implications for the use of
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prophylactic antibiotics which are commonly prescribed to prevent recurrent UTIs and
are often given over long durations at lower doses.
This study provides further evidence which supports a role of antibiotic exposure and
urinary pathogens on the formation of calcium-based stone disease; however, the exact
mechanisms involved have yet to be elucidated. Antibiotics and urinary pathogens may
exert their lithogenic effect through a number of potential mechanisms including
alteration of the gut microbiota, and stimulation of a host inflammatory response29. It is
likely that both these mechanisms influence one another through an interdependent
relationship as the gut microbiota has been shown to affect the inflammatory immune
response and oxidative stress in other disease states30. It has previously been
demonstrated that the microbiota is significantly different in both Drosophila and humans
with calcium-based urinary stones7,31. Alteration of the microbiota may have a negative
effect on oxalate homeostasis by reducing O. formigenes colonization and increasing gut
permeability32. This leads to increased oxalate absorption and subsequent renal oxalate
excretion which results in hyperoxaluria and an increased propensity for stone
formation33-34. Further research investigating the effect of urinary stone disease, urinary
pathogens, and antibiotic exposure on the microbiota are required.
It has also been postulated that alteration of the host inflammatory response by both
bacteria and antibiotics may potentiate stone formation13. Bacterial pathogens are well
known to trigger an immune response resulting in the production of pro-inflammatory
cytokines and ROS35. In addition, similar inflammatory responses, with the release of
pro-inflammatory cytokines [tumor necrosis factor-a (TNF-a) and interleukin-1b (IL1b)] and differentiation of monocytes into inflammatory M1 macrophages, have also
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been observed following exposure to antibiotics such as ciprofloxacin and CaOx
crystals36,37. The inflammatory response triggered by exposure to either a urinary
pathogen or antibiotic exposure may result in renal tubule cell injury and consequently
increased attachment of CaOx crystals. It has previously been demonstrated that
antibiotic treatment induces renal tubular damage and that damaged renal tubule cells
exhibit increased adhesion of CaOx crystals and susceptibility to urinary pathogens38,39.
The complex interplay between urinary bacteria, antibiotics, and CaOx crystals resulting
in alteration of the host immune response may represent a potential mechanism in the
formation of calcium-based urinary stone disease and requires future investigation.
In addition, antibiotics may further potentiate stone formation through a number of other
mechanisms. Crystals of antibiotic substrates within the urine may serve as a nidus of
stone formation through heterogenous nucleation40,41. In addition, antibiotic induced
tubular damage has also been shown to cause hypercalciuria which may further
contribute to stone formation40.
The major limitation of this study is that it is conducted in a non-vertebrate model;
however, DM provide a practical, inexpensive and useful organism for investigating the
pathophysiology of urinary stone disease. The DM Malpighian tubules are the functional
equivalent of human convoluted tubules and have been well studied in regard to solute
transport and excretion mechanisms42. In addition, the Drosophila genome has been
extensively characterized and demonstrated to have significant similarities with the
human genome; thus, providing a powerful tool for the use of genetic engineering
techniques1. The DM model has previously been demonstrated to serve as a useful highthroughput platform in order evaluate the mechanistic pathways of stone formation and
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potential therapeutic agents for lithiasis prevention1,43-44. The findings of our study
utilizing the DM model can now subsequently be confirmed and further investigated in a
murine model followed by human studies.
In conclusion, urinary stone disease is a common condition with a dramatically rising
incidence and a high recurrence rate despite modern treatment and prevention strategies3.
As a result, urinary stone disease represents a tremendous burden on the health care
system11. Further understanding of the pathogenesis of stone disease is necessary.
Specifically, investigating the effect of urinary pathogens, antibiotic exposure and
alterations in the microbiota on urolithiasis may lead to the development of new
prevention and treatment strategies. For instance, cultivation of a robust microbiota with
adequate colonization of O. formigenes may prove to prevent stone formation, and as
such potential strategies for microbiota focused therapy could include antibiotic
stewardship, probiotic therapy, and fecal microbiome transplant (FMT)45,46.
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Chapter 3

3

Defining the Relationship between Urinary Infection and
Urolithiasis: A Novel Role for Osteopontin and Zinc
Transport

There is mounting evidence that the formation of calcium-based stone disease may be
impacted by urinary pathogens. Prior epidemiological studies have demonstrated a
strong association between a history of both culture-proven UTIs and the development of
stone disease. In addition, we have previously demonstrated that exposure to a nonurease producing strain of E. coli increases CaOx stone burden in a Drosophila model
and enhances adherence of CaOx crystals to renal epithelial cells. However, the nature of
the relationship between urinary bacteria and stone disease, as well as the potential
mechanisms involved, have yet to elucidated. Osteopontin which is a known potent
inhibitor of CaOx urolithiasis and Zn which is involved as an early nidus for the
mineralization process of urinary stones; have both also been shown to be involved in
bacterial pathogenesis. We aimed to further investigate the potential effect of a nonurease producing bacteria, and treatment with OPN and Zn on the adherence of CaOx
crystals to renal epithelial cells.
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3.1 Introduction

3.1.1

Role of Osteopontin

Osteopontin is a negatively charged glycoprotein that regulates both physiologic and
pathologic mineralization within the body and has been shown to be a potent inhibitor of
CaOx urolithiasis and play a complex role in urinary stone disease1. It is normal
constituent of the urine, which is synthesized by the kidney and secreted into the urine by
renal epithelial cells of the loop of Henle, the distal tubules and the renal papillae2. It has
been demonstrated to inhibit all steps of stone formation including nucleation,
aggregation and growth of CaOx crystals3. Furthermore, it inhibits the adherence of
CaOx crystals to renal epithelial cells and directs CaOx crystallization towards COD,
which is significantly less adherent to the epithelium4,5. Osteopontin knockout mice
exhibit significantly increased CaOx stone formation in the setting of hyperoxaluria, but
do not spontaneously develop stones6. In addition, clinical studies to date have been
inconclusive regarding the role of OPN in urinary stone disease. Current data support an
important and complex role of OPN in urolithiasis, however, the exact nature of this
relationship has yet to be established.
Osteopontin is also intimately involved in both acute and chronic inflammatory
processes. Pro-inflammatory cytokines, like TNF-a and IL-1b; as well as the activation
of macrophages by lipopolysaccharide (LPS) have been shown to induce OPN gene
expression and protein secretion7. Furthermore, OPN has been implicated in the
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regulation of intestinal inflammation and it is thought to play a role in the maintenance of
the intestinal microbiota by supporting intraepithelial lymphocyte survival8-11.
Osteopontin knockout mice have been shown to have an altered gut microflora and an
accelerated development of colitis10,11. Osteopontin has also been shown to have a
protective effect in polymicrobial endodontic infections by reducing biofilm formation
and increasing phagocyte recruitment12,13. The glycoprotein plays a large role in both
urinary stone disease and the regulation of infectious and inflammatory processes, and
there is growing evidence to suggest that urinary bacteria contribute to the pathogenesis
of calcium urolithiasis. We propose a novel role for OPN in the development of stone
disease, where urinary bacteria potentiate stone formation by altering the host
inflammatory response through the regulation of OPN.

3.1.2

Role of Zinc Transport Proteins

Zinc is an essential trace element that has been implicated as an early nidus for the
mineralization process of urinary stones. It was identified within Randall’s plaques and
urinary calculi in small amounts and is thought to contribute to the process of
heterogeneous nucleation14, 15. Several studies utilizing Drosophila stone models have
demonstrated a potential important role for Zn in urinary stone formation. A diet-induced
CaOx Drosophila stone model revealed an up-regulation of Zn binding proteins with
stone formation14. Furthermore, inhibition of Zn transporter proteins led to a suppression
of stone formation16.
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Zinc is also known to play an integral role in both immune system function and bacterial
pathogenesis17, 18. Exposure of dendritic cells to LPS alters the expression of several Zn
transporters and decreases the intra-cellular availability of Zn19. It has also been shown
that increased Zn levels decrease dendritic cell activation and inhibit the secretion of proinflammatory cytokines normally stimulated by LPS19.
Zinc transport systems play an important role in pathogenesis of UTIs with E. coli
through the modulation of virulence factor expression14,20. In addition, E. coli has been
demonstrated to sequester Zn which may actually form the nidus for further stone
formation21. Zinc is an essential element that plays a vital role in both host immunity and
bacterial pathogenesis and has been implicated as an inciting event of stone formation.
We hypothesize that urinary bacteria enhance CaOx stone formation by altering host Zn
transport mechanisms.

3.2 Methods

3.2.1

Calcium Oxalate Crystal Adherence

Adherence of CaOx crystals to renal epithelial cells was determined with a crystal
adherence assay utilizing MDCK renal epithelial cells (ATCC-CCL-34, NBL-2,
Manassas, VA). MDCK cells were grown to 90% confluence on cell culture plates
(172931, Thermo Fisher Scientific, Waltham, MA) in 5% CO2 at 37°C in Dulbecco’s
Modified Eagle’s medium (DMEM; Thermo Fisher Scientific, Waltham, MA)
supplemented with 10% fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham,
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MA). MDCK cells were exposed to UTI89 (103 CFU) for 20 minutes, and then
incubated with CaOx crystal suspension (0.5 mg/mL) in artificial urine with or without
the addition of OPN (0.1 µg/mL; SRP3131, Sigma Inc., Oakville, Canada), or Zn chloride
(500 µg/mL; 229997; Sigma Inc., Oakville, Canada) for an additional 20 minutes.
Unattached crystals were washed free with culture media and the adherence of CaOx
crystals was determined with birefringence microscopy. The concentrations of OPN and
Zn utilized were consistent with concentrations normally found in human urine22,23.
Further details regarding the experimental protocol are elaborated on in section 2.2.2.

3.2.2

Data Analysis

Birefringent microscopy images of CaOx crystals adhered to the MDCK epithelial cells
were obtained with an inverted light microscope (Nikon Inc., Tokyo, Japan) under a 100x
magnification. MATLAB (MathWorks, 2018) was used to measure pixel intensity of
birefringent CaOx crystals with a threshold pixel intensity of 150. Background pixel
intensity was subtracted for all image analysis. A one-way analysis of variance
(ANOVA) was utilized for statistical analysis with SPSS version 25.0 (IBM, New York,
USA).
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3.3 Results

3.3.1

Calcium Oxalate Crystal Adherence to Renal Epithelial Cells
Following Treatment with Escherichia coli and Osteopontin

As previously demonstrated MDCK cells treated with UTI89 were shown to have a
significantly increased adherence of CaOx crystals (p<0.001). However, exposure to
OPN dramatically reduced adherence of CaOx crystals both in the control and UTI89
treated groups (p<0.001). The effect of OPN on CaOx crystal adherence in the control
treatment is in keeping with OPNs known activity as a stone inhibitor. The ability of
OPN to dramatically decrease CaOx crystal adhesion was consistent in the UTI89 treated
group, demonstrating that OPN is able to negate the effect of E. coli exposure on CaOx
crystal adherence. Representative birefringent microscopy images of CaOx crystal
adherence to MDCK cells following treatment with E. coli UTI89 and OPN are shown in
figure 18. In addition, the mean measured pixel intensity of the CaOx crystals stratified
by treatment group is displayed in figure 19. Details of the ANOVA statistical analysis
for all group comparisons are summarized in tables 15-17.
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Figure 18: Representative birefringence microscopy images of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with
Escherichia coli UTI89 (103 CFU) or osteopontin (0.1 µg/mL) under 100x
magnification.
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Figure 19: Measured pixel intensity of calcium oxalate crystal adherence to MDCK
renal epithelial cells following treatment with Escherichia coli UTI89 (103 CFU) or
osteopontin (0.1 µg/mL). Data displayed as mean ± SEM (n=15/group), * p<0.05
compared with oxalate control., #p<0.05 compared with UTI89.
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Table 15: Mean measured pixel intensity of calcium oxalate crystal adherence to
MDCK renal epithelial cells following treatment with Escherichia coli UTI89 or
osteopontin (0.1 µg/mL).
N
15
15
15
15

Oxalate Control
UTI89
OPN
UTI89 and OPN

Mean
93528.9
177679.7
14868.6
51556.5

SD
45336.1
17104.7
994.2
25519.1

Std. Error
12116.6
4416.4
256.7
658.0

95% CI
Lower
Upper
67352.7 119705.2
168207.4 187151.9
14318.0 15419.1
37424.4 65688.5

UTI89

Table 16: ANOVA analysis of mean measured pixel intensity of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with
Escherichia coli UTI89 or osteopontin (0.1 µg/mL).
Sum of Squares

df

Mean Square

Between Groups

4.903E+11

5

9.806E+10

Within Groups

1.101E+11

84

1.326E+9

Total

1.109E+12

89

F

Sig.

73.936 0.000

Table 17: ANOVA analysis with Tukey post-hoc analysis for multiple group
comparison of mean measured pixel intensity of calcium oxalate crystal adherence
to MDCK renal epithelial cells following treatment with Escherichia coli UTI89 or
osteopontin (0.1 µg/mL).
Mean Difference

Group

Std.

Sig.

95% CI
Lower
Upper

Error

Comparison
Oxalate
Control
UTI89
OPN

-84150.72
78660.4

13533.6
15333.2

0.000
0.000

UTI89 with OPN

126123.2

13298.2

0.000

UTI89

-44668.3
39177.9 118142.8
123633.16
87327.5

164918.9
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3.3.2

Calcium Oxalate Crystal Adherence to Renal Epithelial Cells
Following Treatment with Escherichia coli and Zinc Chloride

In addition to OPN, the potential role of Zn on the relationship between urinary
pathogens and urolithiasis was also investigated. Treatment of MDCK cells with UTI89
resulted in significantly increased adherence of CaOx crystals (p<0.001). Exposure to Zn
chloride significantly increased adherence of CaOx crystals both in the control and
UTI89 treated groups (p<0.05). Co-treatment with both UTI89 and Zn appeared to have
an additive effect of crystal adherence suggesting that Zn is acting to further enhance or
propagate the effect of E. coli on CaOx crystal adherence. Representative microscopy
images of CaOx crystal adherence to MDCK cells following treatment with E. coli
UTI89 and Zn chloride are depicted in figure 20. In addition, the mean measured pixel
intensity of the CaOx crystals stratified by treatment group is graphed in figure 21.
Details of the ANOVA statistical analysis for all group comparisons are summarized in
tables 18-20.
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Figure 20: Representative birefringence microscopy images of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with
Escherichia coli UTI89 (103 CFU) or zinc chloride (500 µg/mL) under 100x
magnification.
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Figure 21: Measured pixel intensity of calcium oxalate crystal adherence to MDCK
renal epithelial cells with Escherichia coli UTI89 (103 CFU) or zinc chloride (500
µg/mL). Data displayed as mean ± SEM (n=15/group), * p<0.05 compared with

oxalate control., #p<0.05 compared with UTI89.
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Table 18: Mean measured pixel intensity of calcium oxalate crystal adherence to
MDCK renal epithelial cells following treatment with Escherichia coli UTI89 or zinc
chloride (500 µg/mL).
N
15
15
15
15

Oxalate Control
UTI89
Zn
UTI89 and Zn

Mean
93528.9
177679.7
160855.9
226337.6

SD
45336.1
17104.7
43440.4
55881.9

95% CI
Lower
Upper
67352.7 119705.2
168207.4 187151.9
136799.4 184912.3
195391.2 257284.0

Std. Error
12116.6
4416.4
11216.3
14428.7

UTI89

Table 19: ANOVA analysis of mean measured pixel intensity of calcium oxalate
crystal adherence to MDCK renal epithelial cells following treatment with
Escherichia coli UTI89 or zinc chloride (500 µg/mL).
Sum of Squares

df

Mean Square

Between Groups

4.903E+11

5

9.806E+10

Within Groups

1.101E+11

84

1.326E+9

Total

1.109E+12

89

F

Sig.

73.936 0.000

Table 20: ANOVA analysis with Tukey post-hoc analysis for multiple group
comparison of mean measured pixel intensity of calcium oxalate crystal adherence
to MDCK renal epithelial cells following treatment with Escherichia coli UTI89 or
zinc chloride (500 µg/mL).
95% CI
Lower
Upper

Mean Difference

Std. Error

Sig.

UTI89
Zn

-84150.72
-67326.9

13533.6
16123.5

0.000
0.000

-123633.16
-106809.3

-44668.3
27844.5

UTI89 with Zn

-48657.9

13298.2

0.006

-87453.7

-9862.2

Group Comparison
Oxalate Control

UTI89

106

3.4 Discussion

The results of this study provide evidence that urinary pathogens impact CaOx crystal
adherence and that both Zn and OPN may be involved in this process with opposing
effects. Exposure of a non-urease producing strain of E. coli to renal epithelia cells
demonstrated a significant increase in CaOx crystal adherence. Both Zn and OPN
significantly affected CaOx crystal adherence individually and in combination with
UTI89. However, they were noted to have opposing effects with Zn increasing CaOx
adherence compared with OPN which reduced crystal adherence.
Consistent with its known role as a stone inhibitor, OPN significantly decreased CaOx
crystal adherence both on its own and in combination with the E. coli. It was observed to
be very potent and dramatically reduce crystal adherence to renal epithelial cells. It
almost completely reversed the accentuated crystal adherence observed with UTI89
exposure.
Osteopontin has previously been demonstrated to inhibit all steps of stone formation
including nucleation, aggregation and growth of CaOx crystals24. In addition to this, it
has also been observed to play an important role in inflammatory processes. The gene
expression and protein secretion of OPN can be induced by multiple pro-inflammatory
cytokines25. It is possible that one of the mechanisms that urinary pathogens use to
potentiate stone disease is through modulation of the host immune response and
subsequent inhibition of OPN. Osteopontin has been shown to play a complex role in
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immune system function and further research is required to elucidate the ways in which
OPN may interact with the inflammatory response to affect stone formation.
Contrary to the effects of OPN, Zn was observed to increase CaOx crystal adherence both
individually and in combination with UTI89. It appeared to have an additive effect with
the E. coli, further potentiating the observed increase in CaOx crystal adherence.
Zinc has been implicated as both a nidus for the mineralization of urinary stones and is
known to be involved in both immune system function and bacterial pathogenesis. It is
thought to serve as a nidus for stone formation through the process of heterogeneous
nucleation26. In addition to this, several studies utilizing DM stone models have
supported an important role for Zn in urolithiasis, with Zn binding proteins being upregulated with stone disease, and genetic inhibition of Zn transport proteins resulting in a
suppression of stone formation26,27.
Along with this, increased Zn levels have been shown to down-regulate the secretion of
pro-inflammatory cytokines and ROS which are normally stimulated by LPS28,29. Given
the role of Zn in both host immunity and bacterial pathogenesis, as well stone formation,
it may play an important role in the relationship between urolithiasis and urinary bacteria.
This is further supported by our data which demonstrate that Zn increased CaOx crystal
adherence and potentiated the effect of E. coli. This suggests that urinary pathogens may
also increase stone formation through the alteration of Zn levels which may serve to
affect the host immune response.
The major limitation of this study is that it is conducted in an in vitro model which
focuses specifically on a single process in the complex cascade of events which occurs
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during the formation of urinary calculi. However, this provides a practical, inexpensive
and useful assay for investigating the pathophysiological mechanisms in urinary stone
disease. It has previously been well described and utilized to study the mechanisms of
urolithiaisis31. In addition, the adherence of CaOx crystals to renal epithelial cells
represents a critical step in the formation of urinary calculi as without this the crystals
would pass through the urinary system without difficulty, and adherence allows for
further aggregation and growth of crystals31. Given that the potential mechanisms
involved in the relationship between urinary pathogens and urolithiasis remain largely
undefined this assay serves as a useful high-throughput platform in order to identify other
potential compounds which may be involved for further investigation.
The influence of urinary pathogens on the formation of urinary calculi likely represents a
complex relationship with multiple contributory mechanisms. Further investigation will
be required in order to better delineate the exact role of both OPN and Zn and to
characterize other potential contributing mechanisms.
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Chapter 4

4

General Discussion

This research showed that a urinary pathogen and antibiotics such as, ciprofloxacin and
TMP-SMX, can have a direct impact on the formation of calcium-based stone formation.
In addition, both OPN and Zn transport proteins may be involved in this process.
However, the exact mechanisms involved remain poorly understood and require further
elucidation.

4.1 Understanding the Relationship between Urinary
Pathogens, Antibiotics and Stone Disease: Implications
for the Host-Inflammatory Response and the Microbiota

Calcium urolithiasis is a complex pathophysiological process which is likely
multifactorial in etiology and involves the interplay of multiple different mechanisms. A
schematic diagram summarizing potential mechanisms involved in the relationship
between urolithiasis, urinary pathogens and antibiotics exposure is depicted in figure 22.
Future research should focus on better characterization of the host inflammatory response
and the microbiota role in response to both antibiotics and pathogens.
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Figure 22: Schematic diagram of potential mechanisms involved in the relationship
between a urinary pathogen, antibiotic exposure, osteopontin, zinc, and the
formation of calcium-based stones.
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4.1.1

The Microbiota and Oxalate Metabolism

The precise relationship between urinary bacteria, antibiotics and stone disease has yet to
be determined; however, it has been postulated that both bacteria and antibiotics alter the
host microbiota thereby potentiating stone formation. This is reflected in the gut
microbiota being significantly different in stone forming patients and those with
1,2

hyperoxaluria . In the Drosophila model used here, the microbiota was also noted to be
significantly different when CaOx stones were present compared to controls. Analysis
with 16S rRNA sequencing demonstrated significantly increased levels of lactobacilli
2

within the microbiota of Drosophila with CaOx urolithiasis . This may actually represent
a compensatory protective mechanism that occurs as a result of stone disease as many
species of lactobacilli are known to degrade oxalate2. Previous work has demonstrated
that certain oxalate metabolizing bacterial species are enhanced in the setting of
hyperoxaluria3. This suggests a greater potential role for the microbiota in the
pathogenesis of stone disease; however, a better understanding of the mechanisms
involved is required.
While many different theories have been proposed, it is likely that antibiotics and
pathogens alter the microbiota and reduce the ability of the gut to maintain oxalate
homeostasis. In support of this, it has been demonstrated that changes to the microbiota
within the small intestine and colon affect increased gut permeability. This would likely
increase the absorption of oxalate and inflammatory bacterial components thereby having
a further potential effect on the formation of stones. Furthermore, colonization with
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beneficial bacteria can serve to reduce stone risk; for instance, it has previously been
shown that gut colonization with Oxalobacter species promotes enteric oxalate secretion
and reduces urinary oxalate secretion4.
Further research is required to better delineate the relationship between stone disease and
the gut microbiota and how this is influenced by antibiotic exposure. Future studies
should focus on the influence of antibiotics on gut permeability and how this may be
improved through the co-administration of probiotics. In addition, FMT with O.
formigenes and other oxalate degrading bacterial species should be investigated as a
potential therapeutic strategy to reduce urinary oxalate levels and thus the risk of stone
disease. Given that enrichment of oxalate metabolizing species may occur as a
compensatory mechanism for hyperoxaluria, increasing oxalate exposure to the
microbiota within the lower gastrointestinal tract may also serve to increase oxalate
degradation within the gut.
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4.1.2

The Host Inflammatory Response

It has been hypothesized that the inflammatory response within the kidney is also altered
by urinary bacteria and antibiotics providing a potential mechanism for enhancing stone
formation4. Bacteria such as E. coli and Proteus mirabilis can reach the kidney when they
cause pyelonephritis; however, studies suggest that they may also exist
asymptomatically5. Bacterial pathogens are well known to trigger an immune response
consisting of M1 macrophage activation which results in the production of proinflammatory cytokines such as IL-1b, IL-12, TNF-a, and ROS6. However, recent data
have demonstrated that exposure of human monocyte cells to CaOx crystals results in a
very similar response with the production of IL-1b, TNF-a, IL-6, and activation of M1
macrophages7. In addition, exposure of the monocyte cells to CaOx crystals followed by
LPS, the major outer surface membrane component of gram-negative bacteria, resulted in
an enhanced inflammatory cytokine expression compared with CaOx crystals alone7.
Furthermore, bactericidal antibiotics such as fluoroquinolones, and b-lactams have been
shown to directly induce the formation of ROS8. The inflammatory cascade triggered by
exposure to either a urinary pathogen or antibiotics may result in renal tubular cell injury
thereby increasing CaOx crystal adhesion to epithelial cells and subsequently increasing
stone formation9,10. This evidence and our data suggests that alteration of the host
immune response from both urinary bacteria and antibiotic exposure may be impacting
the formation of CaOx stones.
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It may be beneficial for future studies to focus on further examining the immune response
and associated with stone disease as well as the exposure to antibiotics, potentially
through next-generation RNA sequencing techniques. In addition, the production of ROS
should also be examined under these conditions. The role of Zn on immune modulation
in stone disease should also be further evaluated.

4.2 Potential Future Strategies

Evidence suggests that alterations in the host immune response may be an underlying
mechanism in the pathophysiology of urolithiasis. Thus, a potential therapeutic strategy
would include substances with anti-oxidant properties which serve to reduce oxidative
stress mediated by ROS, formed as a result of exposure to urinary pathogens or
antibiotics. Future study could examine inflammatory markers in humans following
antibiotic exposure and whether or not this could be affected by the co-administration of
non-steroidal anti-inflammatories.
A prior study demonstrated that the traditional Chinese medicinal plant, Glechoma
longituba, reduced oxidative stress induced by CaOx in renal epithelial cells11.
Additionally, a number of alkyl catechols which are compounds naturally found in
fermented vegetables, ciders, and sourdough breads have been demonstrated to robustly
activate oxidant defense pathways and have been shown to lower urinary oxalate levels
through bacterial metabolism12,13. Consequently, anti-oxidant substances found in
fermented foods may represent a potential treatment strategy for urolithiasis. Further
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study assessing differences in the gut microbiota with fermented food intake may be
enlightening with regards to their potential ability to reduce stone formation.
In addition, given the mounting evidence that the microbiota is implicated in the
development of urolithiasis future strategies for the treatment and prevention of stone
disease will potentially focus on the cultivation and maintenance of a healthy and robust
microbiota which is resilient to stress and has the ability to recover following
perturbation. For instance, strategies for promoting a beneficial microbiota could include
antibiotic stewardship and facilitating dietary diversity which has shown to increase the
robustness of the microbiota14-17.
Another potential strategy would include the use of probiotics in order to reinforce or
support the microbiota. This strategy could potentially work through multiple
mechanisms including improving GI tract barrier function, reducing paracellular oxalate
absorption, and increasing the metabolism and degradation of oxalate. Given the wellestablished role of O. formigenes in oxalate metabolism and its implication with human
urolithiasis, human and in vivo studies have investigated the potential application of
probiotic O. formigenes for the treatment of stone disease. These studies have
demonstrated a significant reduction in urinary oxalate levels following administration of
O. formigenes probiotic in both animal and human studies18-21. While this appears to be a
potentially promising treatment, further study is required to determine the safety and
efficacy21-23.
Other therapeutic options directed at restoring the microbiota include both FMT and
microbiome reconditioning which involves collecting and reconditioning a patient’s own
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microbiota to improve its overall oxalate degrading abilities and then reintroducing it to
them. While the primary use of FMT is currently for Clostridium difficile infection,
assessment of FMT against other diseases are currently underway24-26. It is thought that
FMT may allow for a promising nephrolithiasis treatment as it could potentially restore
intestinal barrier function and oxalate degradation and secretion within the gut. This
would reduce urinary oxalate secretion thereby decreasing the risk of stone formation.
FMT may lead to more durable results than microbiota modification with probiotics, as
previous studies have demonstrated the propensity of gut microbiotas to revert back to
their initial compositions following discontinuation of probiotic therapy27. Similar to
FMT, microbiome reconditioning may allow for restoration of the microbiota without the
potential risks of transmission of unwanted phenotypes or infectious agents that could
occur with allogeneic transplant24,26,27.
With the growing evidence supporting an important role of the microbiota in urinary
stone disease there exist multiple potential promising treatment strategies. However,
before these can be adopted, further investigation is required to better define the exact
mechanistic role of the microbiota in stone disease and how this can be altered to reduce
stone formation.

4.3 Final Conclusion

Urinary stone disease is a common urological condition with a dramatically rising
incidence among all age groups28. Despite modern treatment and prevention strategies
urolithiasis continues to have a high recurrence rate thus resulting in considerable patient
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morbidity and a tremendous burden on the health care system29. An improved
understanding of the pathophysiology underlining urolithiasis is paramount and should
focus on the potential alteration of the host inflammatory response and microbiota in
urinary stone disease. The present thesis suggests that further investigation into how
disruption of urinary and gut microbes occurs, including through antibiotic
administration, could be revealing. This perturbation may then lead to damaged gut
barrier function, inflammation, and propagation of non-oxalate degrading organisms
which may result in increased stone formation. Furthermore, this research may help to
identify potential new therapeutic targets and strategies for urolithiasis, including
antibiotic stewardship, anti-oxidants, probiotics, and microbiome modification.
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Appendices

Appendix A1: Abbreviations

ANOVA

Analysis of variance

CaOx

Calcium Oxalate

CFU

Colony forming unit

CO2

Carbon dioxide

COD

Calcium oxalate dihydrate

COM

Calcium oxalate monohydrate

DM

Drosophila melanogaster

DMEM

Dulbecco’s Modified Eagle Media

E. coli

Escherichia coli

FBS

Fetal bovine serum

FMT

Fecal microbiome transplant

H. pylori

Helicobacter pylori

IL-1b

Interleukin-1 beta

LPS

Lipopolysaccharide

MDCK

Madin-Darby Canine Kidney

NaOx

Sodium Oxalate

O. formigenes

Oxalobacter formigenes

OPN

Osteopontin

PBS

Phosphate buffered saline

PTH

Parathyroid hormone

ROS

Reactive oxygen species

TMP-SMX

Trimethoprim-sulfamethoxazole

TNF-a

Tumor necrosis factor-alpha

UTI

Urinary tract infection

Zn

Zinc
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